Retatrutide
Other names: LY3437943
Retatrutide’s “triple G” effect could make this medication more potent than its rivals. This injectable drug showed incredible results during the experimental stage, helping patients lose up to 24% of weight (almost 60 pounds) in 48 weeks. These are the highest results ever seen in anti-obesity medication to date. It is encouraging news for the many people who have practically given up trying to lose weight.
◐ Production capacity: Provide customization
◐ Large Factory Professional Manufacturers & Factory
◐ Production Carried OUT Under CGMP Regulation and Trackable
◐ ISO9001 & ISO14000
SHARE THIS
Get a Bulk quotation
If you need a larger quantity. Please fill in the form, our BD (Business Development) will provide you with a competitive quotation.

Properties
Description
Manufacturers/Factory
Coa & MS
Where to buy?
FAQ
Reviews
Properties
Sequence: | Tyr- {Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile- {α-Me-Leu}-Leu-Asp-Lys- {diacid -C20-gamma-Glu-(AEEA)-Lys}-Ala-Gln- {Aib}-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly -Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 |
Molecular Formula: | C223H343F3N46O70 |
Molecular Weight: | 4845.444 g·mol−1 |
PubChem CID: | 474492335 |
CAS Number: | 2381089-83-2 |
Synonyms: | LY3437943 |
Description
Retatrutide structure
Source Origin:Wiki
There are some peptides medications for weight loss already in the market. They are Semaglutide powder-based drug and Tirzepatide. However, more novel medications are coming down the pipeline that will further revolutionize obesity medicine, Retatrutide may become one of the most effective weight loss peptides.
In June 2023, Eli Lilly pharmaceutical company released the latest results from a novel drug called retatrutide. The drug, helped patients lose an average of 24% of their body weight over the course of 48 weeks on the highest dosage 12mg.While this medicine is still in the early stages of development, the extraordinary weight loss outcomes from clinical studies have everyone’s attention. To buy retatrutide powder to do the research, ensure to buy it from the peptide manufacturer Polypeptide.Ltd.[1]
What is Retatrutide?
Retatrutide (LY-3437943) is an experimental drug for obesity developed by American pharmaceutical company Eli Lilly and Company. Also known as GGG Tri-agonist, GLP-1/GIP/glucagon tri-agonist, or LY3437943, this injectable medication is set for FDA approval. Retatrutide is in the same class as other weight loss drugs like Semaglutide and Tirzepatide. However, what sets it apart from other obesity medications is that it targets three hunger-reducing hormones. Semaglutide only targets one hunger-controlling hormone called GLP-1, while Tirzepatide targets GLP-1 and GIP. Retatrutide takes it a notch higher by targeting three hunger-regulating hormones: GIP, GLP-1, and glucagon receptor.[2]
If single or dual receptor agonist drugs are already effective, this triple-agonist, or triagonist, new molecular entity promises to deliver even greater results. That will be very helpful for individuals struggling with obesity or, for example, those who are not losing weight on Semaglutide and Tirzepatide. Since Retatrutide hasn’t available from Eli Lilly, If you want to start your own research on Retatrutide peptide, please make sure to buy it from a reputable Retatrutide powder supplier. Buy Retatrutide powder bulk will get a good price.[3]
What are receptor agonists?
To understand mechanism of action behind retatrutide, it’s essential to familiarize yourself with the concept of receptor agonists. Let’s commence by offering a swift delineation of receptors—they stand as protein entities adorning the exterior of our cells. These receptors serve as conduits for signals arriving from the extracellular milieu. These signals may originate from neurotransmitters, hormones, or even pharmaceutical compounds. Upon binding, these substances communicate pertinent information to our cells. In response to this information influx, our cells become activated and initiate appropriate actions. For instance, hormones like ghrelin and leptin, which are intricately linked to appetite, either stimulate our cravings or communicate satiety post-meal. The absence of functional receptors would render our cells oblivious to these crucial cues.
Receptor agonists constitute a class of compounds, encompassing medications or chemical agents, engineered to engage with cell receptors and incite a specific reaction. These agonists could be either naturally derived or artificially synthesized, with hormones and neurotransmitters serving as paradigmatic instances of natural agonists.[11]
Understanding how does Retatrutide work?
Depending on which cell receptors they bind to, different receptor agonists play distinct roles in our bodies. Retatrutide, as previously stated, stimulates three receptor agonists: GLP-1, GIP, and glucagon. To gain a better grasp of retatrutide mechanism of action, you should first learn about receptor agonists. Here’s how each one works in our bodies and why they help with weight loss:
GLP-1 (Glucagon-like Peptide-1):
Glucagon-like peptide-1 (GLP-1) emerges as an intestinal peptide hormone that our body generates in response to meal consumption. This hormone assumes a versatile role, with its primary significance lying in the regulation of food intake and hunger sensations. As we partake in a meal or a snack, the elevation of our blood glucose levels triggers the release of GLP-1, setting in motion the stimulation of insulin secretion from the pancreas.[4]
Insulin, a pivotal hormone manufactured by our body, functions as the key to unlocking cellular entry for glucose originating from dietary intake. The cells’ reliance on glucose as their chief energy source for fundamental processes underscores the critical role of insulin. Its role extends to the meticulous management of blood sugar levels and its implications for weight management. The absence of sufficient insulin erects barriers to glucose ingress into cells, not only impeding nutrient absorption but also leading to escalated blood sugar levels. Consequently, surplus glucose metamorphoses into adipose tissue, contributing to weight gain.
GLP-1 orchestrates the promotion of insulin secretion from the pancreas while simultaneously orchestrating the curtailment of glucose release from the liver. Beyond its contributions to glucose moderation, GLP-1 orchestrates a deliberate deceleration of gastric emptying, inducing a protracted digestive journey. This translates to a hastened sense of satiety and contentment following meals. Furthermore, GLP-1 exercises its influence on the brain’s hunger center, instigating a reduction in the sensation of appetite. These dual facets of GLP-1’s influence work in concert to quell hunger, akin to the mechanisms of appetite suppressants like Phentermine, often employed to foster weight loss endeavors.
GIP (Glucose-Dependent Insulinotropic Polypeptide):
Just as GLP-1, glucose-dependent insulinotropic polypeptide (GIP) belongs to the family of incretin hormones. Hence, both these peptide hormones exhibit strikingly similar behaviors. This hormone is generated within the small intestine following a meal, where it homes in on the pancreatic beta cells, effectively triggering the discharge of insulin. This action contributes to the regulation of post-meal blood sugar levels. Nevertheless, GIP’s sojourn within our system is brief; it undergoes breakdown in approximately 7 minutes. GIP receptor agonist medications, exemplified by Mounjaro, are designed to sustain elevated GIP levels in our bloodstream, extending its presence. This hormone induces a gradual-paced gastric emptying process while concurrently curbing appetite. Its influence extends to both the brain and the digestive system. That is why the stomach is one of the best place to inject Tirzepatide for weight loss.[10]
Glucagon receptor:
Glucagon, an additional hormone of paramount significance, assumes a pivotal role in the orchestration of blood sugar levels. Analogous to GLP-1 and GIP, its origin lies within the pancreas, although it emanates from a distinct variety of cells known as alpha cells. In stark contrast to the aforementioned hormones, glucagon operates in a manner diametrically opposed. When our blood sugar levels begin to ebb, prompted by factors such as fasting or slumber, glucagon initiates the conversion of glycogen—the reserved form of sugar—into glucose, thus providing our body with a readily accessible fuel source. Although insulin and glucagon wield divergent effects, they collaborate in tandem to uphold optimal sugar levels. Insulin channels sugar into glycogen, while glucagon undertakes the converse.[12]
How does glucagon contribute to weight loss? Our system stockpiles surplus glucose from dietary intake as both glycogen and adipose tissue. During prolonged intervals devoid of carbohydrate consumption—during periods of sleep, adherence to a low-calorie regimen, or intermittent fasting, for instance—glucagon emerges as a vital player, endeavoring to engineer glucose generation. This process commences by dismantling glycogen reserves; once this reservoir is depleted, glucagon turns its focus to the disintegration of fat stores, converting them into a usable energy source.
Retatrutide weight loss facts – What are the clinical results of Retatrutide?
Phase II trial
In recent results from its Phase II trial (NCT04881760), data showed that after 48 weeks, in the retatrutide dosage 1mg, 4mg, 8mg, and 12mg groups, -8.7%, -17.1%, -22.8%, and -24.2% percentage change in body weight was recorded. Furthermore, a weight reduction of 15% or more was recorded in 60% of subjects in the study. With regards to safety, the most common adverse events were of a gastrointestinal nature, and thus retatrutide’s safety profile was on par with other incretin-based therapies.[9]
A Phase III trial (TRIUMPH-3; NCT05882045) began in May, studying the effects of retatrutide in patients with severe obesity and established cardiovascular disease, and is estimated to end in November 2025.
Retatrutide benefits – Retatrutide vs Tirzepatide vs Semalgutide
Again, research into retatrutide peptide is ongoing. But data so far show that retatrutide may help people lose even more weight than other Tirzepatide and Semaglutide. According to previous research on people, here are some of the clinical trials results:
Novo Nordisk’s semaglutide was found to reduce body weight, on average, by around 15%, or about 34 pounds, after 68 weeks.
And Lilly’s other weight loss drug, tirzepatide, was shown to reduce body weight, by 22.5% on average, or about 52 pounds, after 72 weeks.
The experimental drug, retatrutide, helped people lose, on average, about 24% of their body weight, the equivalent of about 58 pounds,after 48 weeks. However, this is a limited-time effect, and the actual Retatrutide benefits could be even better. Phase three trials would reveal the full potential and long-term effects, making it easy for people to trust it.[8]
To be sure, these are not direct comparisons because the drugs were not compared in a head-to-head clinical trial. What benefits we can expect from Retatrutide powder are weight loss and type 2 diabetes treatment. But Retatrutide has the potential to work faster and more effectively than Tirzepatide and Semaglutide.
Is Retatrutide powder available?
Retatrtide is new weight loss drug on the horizon of 2023, but it hasn’t available from its original company Eli Lilly. Retatrutide peptide is up for approval from the Food and Drug Administration because it has to complete longer phase three trials, which can last up to2025. Retatrutide is not appropriate or available for everyone. Some customers find the once-week injection and the Retatrutide price to be prohibitively expensive. Additionally, the drug may only available via prescription. This opens up a big market for Retatrutide over-the-counter substitutes.
After Eli Lilly shared the results of Retatrutide phase II trial, more and more peptide suppliers are eager to try to produce Retatrutide powder. Now there are Retatrutide powder for sale online. The researchers may have concerns about the online retatrutide powder quality from the online peptide suppliers.To verify Retatrutide powder quality, you can simply buy affordable Retatrutide lyophilized powder to do the test first. Retatrutide peptide is available in Polypeptide.Ltd in raw powder form and lyophilized powder form.[7]
What are the side effects of Retatrutide
Retatrutide is synthetic peptide, primarily available in the form of raw powder and finished vials. in supplier Polypeptide.Ltd. Despite the high efficiency, there are risks regarding retatrutide injections.
It is an injectable medicine that looks to be safe for managing short-term weight loss. However, some people may develop modest to moderate adverse effects, such as gastrointestinal difficulties, in different individuals.
Patients who lose weight rapidly – more than 10 pounds per month – may be at risk of developing gallstones.[13]
Retatrutide’s side effects were comparable to those of other weight loss drugs, including nausea, vomiting, diarrhea, and constipation. People frequently encounter those adverse effects as they increase the dosage at the start of treatment, but they normally go away after a while.
The study mentioned certain retatrutide side effects, which tended to be more severe at higher doses. Among them were:
Nausea
Diarrhea
Vomiting
Constipation
The researchers stated in the study that the symptoms were “mostly mild to moderate in severity” and that they were less severe when individuals were given a lower initial dose of 2 mg rather than 4 mg.[6]
Skin tingling was noted in 7% of patients, and an increase in heart rate was reported in the retatrutide group for up to 24 weeks (it decreased after 24 weeks).
Retatrutide manufacturer | Where to buy Retatrutide powder?
Novo Nordisk is the main competitor of Eli Lilly, with products like Wegovy and Ozempic, already in use for obesity control. Ozempic is also an injectable medication, and its trials show up to 15% efficacy, which is substantially lower than retatrutide clinical trials. Though the trial results are encouraging, it will likely be years(2025) before retatrutide is approved by the Food and Drug Administration.
Retatrutide Eli Lilly is one of the leading names, as promised by the trials. However, it is also an inspiration for more drug developers to develop something equally good or better. Now Retatrutide powder can be purchased online. Polypeptide.ltd as one of the Retatrutide powder manufacturers, first developed Retatrutide powder. First batch Retatrutide powder available in 5mg/vial. If you decide to buy Retatrutide powder for research from Polypeptide.Ltd manufacturer, it is important to get test report such COA to verify the product quality.[5]
Manufacturers/Factory
People who may not respond well to other weight loss drugs may benefit from retatrutide powder. Given its potency, it may also be beneficial for persons who need to shed a significant quantity of weight. Still, retatrutide has a long way to go before it can be made available to the general population. Investigators who want to find a reputable Retatrutide powder manufacturer, Polypeptide.Ltd is the right place for you. As the best Retatrutide powderFactory, Polypeptide.ltd is not only supply the Retatrutide raw powder but also finished vials for research.
Coa & MS
Where to buy?
Many people who want to use Retatrutide cannot afford it, while others may not be fat enough to get a prescription. Both of these issues are likely to lead to huge demand for over-the-counter (OTC) Retatrutide alternatives that are easier to obtain and less expensive to use. Where to buy affordable Retatrutide powder. Polypeptide.Ltd will one of the supplier you don’t want to miss.
What Are The Advantages If Buy Retatrutide From Polypeptide.ltd?
- Competitive Factory Price-Factory direct sales, No middlemen make a difference.
- Customization Service-Product specifications can be customized to create your own peptide brand.
- Quality Guarantee-Professional lab reports along with shipment.
- Fast Shipping-Professional logistics customization solutions, on-time delivery.
- Easy Payment-Payment methods that are diverse.
- 365/24/7 Service-High quality pre-sales and after-sales service, followed by product and order details consultation.
How To Get The Quick Price Of Retatrutide Online?
- Visit professional Retatrutide supplier Polypeptide.ltd, choose the Retatrutide you want to buy.
- Leave your contact and message on polypeptide.ltd website, then submit to polypeptide.ltd.
- The customer service will reply you in 12 hours once received your message, then talk in details about buy Retatrutide.
Does Polypeptide.ltd Support The Free Sample Of Retatrutide Powder?
It depends, different products with different policy, please check it with our customer service. Most of products can be accepted for sample.
Can I Appoint The Retatrutide Colour When Buy Retatrutide?
YES! Polypeptide.ltd as peptide manufacturer, provide colour customization of Retatrutide, easy to help you to build your Retatrutide peptide brand.
Can I Appoint The Products Standard When Buy Retatrutide From Polypeptide.ltd?
YES! As one of the best Retatrutide manufacturer, Polypeptide.ltd not only provide the standard specification of Retatrutide in 5mg, 10mg, but support standard customization. Provide the best support to build your own Retatrutide brand.
Can I Buy Retatrutide In Pure Powder Form From Polypeptide.ltd?
YES! Retatrutide powder is the base that use for Retatrutide lyophilized powder manufacture. Polypeptide.ltd provide Retatrutide in both of pure powder form and semi-finished vial form.
Can I Buy Discount Retatrutide Powder From Polypeptide.ltd?
YES! Our factory produce high quality Retatrutide powder in term and keep Retatrutide powder in stock. You can buy high quality Retatrutide powder in bulk. During promotion sale, you can buy Retatrutide peptide by lower price. You can keep touch with our customer manager and they will update the latest bulk Retatrutide price for you in time.
FAQ
What is retatrutide?
Retatrutide is a new weight loss drug produced by Eli Lilly and Company in the United States, and is also known as a GGG tri-agonist. Retatrutide peptide has not received FDA[1][3][6] approval. The injectable drug showed incredible results during its experimental phase, helping patients lose 24 percent of their body weight (nearly 60 pounds) in 48 weeks. [2][5][7]These are the highest results ever seen with an anti-obesity drug.
What is the purpose of retatrutide clinical trials
The primary objective of the Retatrutide clinical trial study is to evaluate the efficacy and safety of once-weekly retatrutide in participants with obesity and established cardiovascular disease (CVD). In this regard, the Phase II trial and Phase III trial conducted by Eli Lilly and Company showed that the effect of Retatrutide was significantly more effective than the control group. It can effectively treat obesity through GGG tri-agonist, which can be said to be an upgraded version of Tirzepatide and Semagutide.
Why is Retatrutide called ggg tri-agonist?
Retatrutide differs from other obesity drugs in that it targets three hunger-reducing hormones: GIP, GLP-1, and glucagon receptors. Therefore, it is also called GGG tri-agonist.[10][13][14]
Glucagon-like peptide-1 (GLP-1) is a gut peptide hormone that our bodies produce in response to eating food. This hormone has a variety of effects,[11][12] its primary significance being in regulating food intake and hunger. When we eat a meal or snack, rising blood sugar levels trigger the release of GLP-1, [7[8]which stimulates the pancreas to secrete insulin
Like GLP-1, glucose-dependent insulinotropic polypeptide (GIP) belongs to the incretin hormone family. Therefore, these two peptide hormones exhibit strikingly similar behavior. This hormone is produced in the small intestine after a meal, where it resides on pancreatic beta cells, effectively triggering the release of insulin. This effect helps regulate blood sugar levels after meals.
Glucagon is another vital hormone that plays a key role in the regulation of blood sugar levels. Like GLP-1 and GIP,[1][2][3] it originates in the pancreas, although it is derived from a unique type of cell called alpha cells. In stark contrast to the above hormones, glucagon works in the exact opposite way. When our blood sugar levels begin to drop due to factors such as fasting or sleep, glucagon initiates the conversion of glycogen (the retained form of sugar) into glucose,[5][10][11] providing our bodies with an easily accessible source of fuel.
What is Eli Lilly’s new weight-loss drug?
Eli Lilly and Company has launched a powerful new weight-loss drug called Retatrutide. And the experimental research of this drug achieved breakthrough data – helping patients lose about 24% of their weight, setting a new standard for weight loss in subsequent clinical trials.
What are the conditions for retatrutide trial sign up?
Participants who sign up for the trial must:
Being overweight.
Have heart disease, stroke, or peripheral artery disease.[10][11][12]
History of at least 1 failed self-reported weight loss dietary effort.
Participants who sign up for the trail must not:
Have had the following conditions within 90 days before screening: heart attack, stroke, hospitalization for congestive heart failure or unstable angina.
Have taken any weight loss medications, including over-the-counter medications, within 90 days before screening.
Weight change of more than 11 pounds in 90 days.
Have had or are planning to have surgery for excess weight.
Have type 1 diabetes.
Have a family or personal history of medullary thyroid cancer (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
Have had pancreatitis.
What are the results of Retatrutide phase 2?
The Phase 2 trial of retatrutide is designed to evaluate its efficacy,[11][12][14] tolerability and safety at different doses and dose escalation schedules in obese patients. The study lasted 48 weeks and was a randomized, double-blind, placebo-controlled trial. In the United States, the study randomly selected 338 participants in a 2:1:1:1:1:2:2 ratio. Each participant received 1 mg of retatrutide (initial dose of 2 mg), 4 mg (initial dose of 2 mg), and 4 mg. 4 mg, 8 mg (initial dose 2 mg), 8 mg (initial dose 4 mg), 12 mg (initial dose 2 mg), or placebo were administered subcutaneously once weekly for 48 weeks. [6][8][9]Percent change in body weight from baseline at 24 weeks was the primary endpoint.
Results from Eli Lilly’s Phase 2 study of Retatrutide, published in the New England Journal of Medicine, showed that the study molecule reduced average weight loss by 24%(at the highest dose) in obese and overweight adults over 24 weeks.
What are the results of Retatrutide phase 3?
This phase 3 multinational multicenter trial will evaluate the weight loss and cardiovascular event outcomes of retatrutide, a triple agonist administered subcutaneously once a week to stimulate GLP-1, GIP and glucagon receptors.[8][9][10] The study,
which began in May and is still ongoing, is expected to end in November 2025.
Where to find Retatrutide coupon?
Polypeptide.ltd has been producing high-quality Retatrutide powder for a long time and has Retatrutide powder in stock. You can buy high-quality retarglutide powder in bulk. [1][4][8]During promotions, there will be coupons through which you can buy Retatrutide at a lower price.
What is the difference between Tirzepatide and Retatrutide?/Retatrutide Vs Tirzepatide
Retatrutide works more effective than Tirzepatide. Tirzepatide is dual GIP/GLP-1 receptor agonist only.[11][12][13] Retatrutide takes it a step further by also mimicking the glucagon receptor.
Comparison of action mechanisms:
Retatrutide – Retatrutide achieves its desired effects by targeting three hunger-regulating hormones: GIP, GLP-1, and glucagon receptors. When blood sugar levels rise, GLP-1 and GIP help lower blood sugar levels.[1][5][6] Glucagon does the opposite. When blood sugar levels drop, our bodies can help raise them. People with type 2 diabetes can use GIP and GLP-1 to control blood sugar. People with this disease are unable to manage insulin properly, resulting in high blood sugar. These two hormones stimulate the pancreas to release insulin after eating, which prevents the liver from producing extra glucose. Additionally, GLP-1 and GIP help reduce gastric emptying. When you eat, food moves through your digestive system more slowly, and you stay fuller longer.
Tirzepatide – aids weight loss by suppressing appetite. Blood sugar levels can be lowered to healthier levels through GIP and GLP-1. This helps control blood sugar levels in diabetics and slows the rate at which food leaves the stomach. The best place to inject Mounjaro for weight loss is in the abdomen, since most of the effects of tezepatide are done in the intestines. Additionally, GLP-1 and GIP affect hunger areas of the brain, thereby reducing appetite.
Dosage and usage comparison:
Retatrutide – Experiments are still ongoing and therefore the exact dosage has not yet been determined. However, according to clinical trials, the lowest dose should start from 1mg-4ng per week, and the highest dose is 12mg.
Tirzepatide – 2.5 mg injected once a week. Thereafter, the dose is increased monthly until the dose reaches a maximum of 15 mg.
Comparison of weight loss effects:
Retatrutide – According to research, Retatrutide can achieve 24.2% weight loss in 48 weeks. [7][8][10]Compared with other weight loss drugs, this drug can achieve greater weight loss and achieve the goal in less time.
Tirzepatide – According to patient feedback, this drug can reduce body weight by 5% at the lowest dose and up to 22% at approximately 72 weeks at the highest dose.
What is the Retatrutide brand name?
Since the Phase III trial of Retatrutide is still ongoing and has not yet been approved by the FDA, it does not have a brand name yet. The current official name is still Retatrutide.[1][2][3]
When will retatrutide be available?
Now! ! !
As one of the best Retatrutide manufacturers, Polypeptide.ltd not only supplies Retatrutide peptides of different specifications, but also provides standard customization services,[4][6][7] which can provide full support for you to build your own Retatrutide brand.
Here you can not only get Retatrutide lyophilized powder , but you can also buy Retatrutide raw powder.
What are the benefits of Retatrutide peptide?
Retatrutide peptide is a newly launched weight loss drug, and its benefits are still being studied. Based on current research data, the known benefits of Retatrutide are as follows:
- Promote weight loss. As a weight loss drug, Retatrutide’s Phase II clinical trials have shown that it can help reduce weight by 24% at the highest dose. [10][11][12]Its weight loss effect far exceeds that of Tirzepatide and Semaglutide in the same series.
- Prevent fatty liver disease related to metabolic dysfunction. Relevant personnel said that Retatrutide can reduce liver fat in the early stages of liver disease and “”skim”” the liver, thereby reducing the long-term damage caused by liver disease to other functions (heart, metabolism, kidneys, etc.).
- Effectively manage type 2 diabetes. [8][9][10]One way to assess blood sugar control is with a glycated hemoglobin test (HbA1C). Data from studies on retatrutide provide averages of patients’ blood sugar levels over three months. It was shown that after 36 weeks, patients who received the highest dose had an average reduction in HbA1C levels of 2.16%.”
Does Retatrutide really work for weight loss?
Yes
Obese patients who received injections of Retatrutide, an agonist of GLP-1, GIP and glucagon receptors, lost more weight than those who received a placebo, according to results from a phase 2 trial.
By week 24, participants who received 12 mg (the highest dose) had lost 18% of their weight, while those who received placebo had lost only 1.6% during the same period. At 48 weeks, the 12 mg retatrutide group experienced an average weight loss of 24%.
What are the results of Retatrutide study?
The current Retatrutide studies includes clinical phase 2 and ongoing phase 3.
Clinical phase 2 experimental data shows the amazing weight loss effect of Retatrutide. The data showed that after 48 weeks, the percentages of recorded body weight changes were -8.7%, -17.1%, -22.8% and -24.2% in the 1mg, 4mg, 8mg and 12mg groups, respectively. Additionally, 60% of the subjects in the study lost 15% or more of their body weight.
Phase 3 clinical trials began in May, focusing on the effects of Retatrutide on severe obesity and established cardiovascular disease. [5][7][9]The experiment is expected to end in November 2025.
When did Retatrutide get FDA approval?
Retatrutide is a gastric inhibitory polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptor agonist being developed for the treatment of obesity. Eli Lilly is still testing Retatrutide in clinical trials and may not apply for FDA approval for months.[2][4][6]
What is the structure of Retatrutide?
Retatrutide is designed by mimicking the natural structure of human parathyroid hormone, which is essential for maintaining bone health. It consists of two components linked together by disulfide bonds: an aminosalicylic acid moiety and a nonapeptide that interacts with PTH receptors. Due to its unique structure, Retatrutide binds to its target receptors more effectively than traditional therapies. This is because it is more stable and bioavailable.
Does Retatrutide cause side effects?
Yes
The side effects of Retatrutide are generally consistent with those of other weight loss drugs, and may be accompanied by adverse reactions such as nausea, vomiting, diarrhea, and constipation during use. However, these reactions will slowly disappear as the time of use increases.Studies have shown that the higher the dose, the more severe the side effects.
Will you jump from Mounjaro to retatrutide when it’s approved?
Some say no. Because Retatrutide is expensive and, as a new weight loss drug, it is not yet covered by insurance.
But some people have indicated that they will switch to using Retatrutide, because as far as the current research is concerned, the weight loss effect it shows has attracted a lot of people’s attention. Many people, especially obese patients who have used other weight loss drugs but had no obvious effects, expressed their willingness to Try this medicine.
There are still some people who are still hesitant, worried that this powerful weight loss drug will cause great damage to the body.
What is the Retatrutide mechanism of action?
Retatrutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. However, Retatrutide also promotes insulin by targeting the glucagon receptor (GCGR) and gastric inhibitory peptide receptor (GIPR). Through this tripartite mode of action, Retatrutide induces glucose-dependent insulin release from the pancreas via the GLP-1 receptor, enhances this GLP-1-mediated effect via the GIP receptor, and increases energy expenditure via the glucagon receptor.
GLP-1: This is a gut peptide hormone that is produced by itself in response to eating. [9][11][12]This hormone plays a variety of roles, primarily regulating eating and hunger.
GIP: Like GLP-1, GIP belongs to the incretin hormone family. This hormone is produced in the small intestine after eating and effectively triggers the release of insulin, which helps regulate post-meal blood sugar levels. This hormone also induces gastric emptying, thereby suppressing appetite.
Glucagon Receptors: In contrast to the previous two, when our blood sugar levels drop, glucagon is converted into glucose to provide energy to our bodies. When carbohydrates are not consumed for a long time, glycogen stores will begin to be dismantled. Once the stores are dismantled, glucagon will focus on breaking down fat stores to achieve weight loss.
What is the use of retatrutide?
Retatrutide (LY-3437943) is being developed to treat type 2 diabetes, obesity, and non-alcoholic fatty liver disease.
Who Should Take Retatrutide?
Based on the current retatrutide clinical trials, it is clear that anyone over a BMI of 27 can take it for weight loss.[9][10][11]
Can I get a prescription for Retatrutide?
It should be noted that retatrutide is currently an investigational medicine that is being researched. This means that you cannot be prescribed it at this time.
Reviews
Retatrutide Peptide dosage calculator
Referenced Citations
[1]Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML; Retatrutide Phase 2 Obesity Trial Investigators.”Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial.”N Engl J Med. 2023 Aug 10;389(6):514-526. doi: 10.1056/NEJMoa2301972. Epub 2023 Jun 26.PMID: 37366315
[2]Doggrell SA.”Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?”Expert Opin Investig Drugs. 2023 May;32(5):355-359. doi: 10.1080/13543784.2023.2206560. Epub 2023 Apr 24.PMID: 37086147
[3]Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, Thomas MK, Hartman ML, Haupt A, Milicevic Z, Coskun T.”Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.”Lancet. 2023 Aug 12;402(10401):529-544. doi: 10.1016/S0140-6736(23)01053-X. Epub 2023 Jun 26.PMID: 37385280
[4]Harris E.”Triple-Hormone Combination Retatrutide Induces 24% Body Weight Loss.”JAMA. 2023 Jul 25;330(4):306. doi: 10.1001/jama.2023.12055.PMID: 37405802
[5]Urva S, O’Farrell L, Du Y, Loh MT, Hemmingway A, Qu H, Alsina-Fernandez J, Haupt A, Milicevic Z, Coskun T.”The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying.”Diabetes Obes Metab. 2023 Sep;25(9):2784-2788. doi: 10.1111/dom.15167. Epub 2023 Jun 13.PMID: 37311727
[6]Urva, S., Coskun, T., Loh, M. T., Du, Y., Thomas, M. K., Gurbuz, S., Haupt, A., Benson, C. T., Hernandez-Illas, M., D’Alessio, D. A., & Milicevic, Z. (2022). LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet (London, England), 400(10366), 1869–1881. https://doi.org/10.1016/S0140-6736(22)02033-5.
[7]Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, Urva S, Gimeno RE, Milicevic Z, Robins D, Haupt A.”Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.”Lancet. 2018 Nov 17;392(10160):2180-2193. doi: 10.1016/S0140-6736(18)32260-8. Epub 2018 Oct 4.PMID: 30293770
[8]”Lilly’s phase 2 retatrutide results published in The New England Journal of Medicine show the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity and overweight” (Press release). Eli Lilly. 26 June 2023. Retrieved 3 July 2023.
[9]Constantino, Annika Kim (26 June 2023). Eli Lilly experimental obesity drug could beat rivals in total weight loss for patients. CNBC. Retrieved 3 July 2023.
[10]Ajit Regmi, William Roell.”Differentiation of human subcutaneous adipocytes and measurement of lipolytic function induced by GIP or LY3437943.” https://doi.org/10.1016/j.xpro.2023.102304
[11]Clifford J. Bailey, Peter R. Flatt , J. Michael Conlon.”An update on peptide-based therapies for type 2 diabetes and obesity.” https://doi.org/10.1016/j.peptides.2023.170939
[12]Peter M. Clifton.”Cutting Edge Developments in Diabetes.” Diabetology 2023, 4(3), 278-281; https://doi.org/10.3390/diabetology4030024.
[13]Rajmohan Seetharaman and Swarnima Pandit. Breaking the mold: revolutionary new obesity drugs set to transform treatment landscape?” From the journal Journal of Basic and Clinical Physiology and Pharmacology.https://doi.org/10.1515/jbcpp-2023-0172
[14]What You Need to Know About Reconstituting Tirzepatide Peptide Step By Step
Author of this article:
Dr. Jean Zeng graduated from king’s college london Faculty of Life Sciences & Medicine.
Scientific Journal paper Author:
Velocity Clinical Research at Medical City, Dallas, TX, USA
School of Pharmacy and Medical Sciences, Gold Coast Campus, Griffith University, Gold Coast, Queensland, Australia
Eli Lilly and Company, Indianapolis, Indiana, USA
Velocity Clinical Research, Los Angeles, CA, USA
Insulin Discovery, Eli Lilly and Company, Indianapolis, IN 46225, USA
In no way does this doctor/scientist endorse or advocate the purchase, sale, or use of this product for any reason. Polypeptide.ltd has no affiliation or relationship, implied or otherwise, with this physician. The purpose of citing this doctor is to acknowledge, acknowledge and commend the exhaustive research and development work done by the scientists working on this peptide.
Author of this article:
Dr. Jean Zeng graduated from king's college london Faculty of Life Sciences & Medicine.
Scientific Journal paper Author:
Stephen C. Bain
Diabetes Research Group, Swansea University Medical School, Swansea, SA2 8PP, UK
Department of Diabetes and Endocrinology, Singleton Hospital, Swansea Bay University Health Board, Swansea, SA2 8QA, UK
In no way does this doctor/scientist endorse or advocate the purchase, sale, or use of this product for any reason. Polypeptide.ltd has no affiliation or relationship, implied or otherwise, with this physician. The purpose of citing this doctor is to acknowledge, acknowledge and commend the exhaustive research and development work done by the scientists working on this peptide.
Related products
/
/
/
/
Reviews
There are no reviews yet.